Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07121335) titled 'SMC Radiation Oncology SABR Cohort for Oligometastasis' on Aug. 4.
Study Type: Observational [Patient Registry]
Primary Sponsor: Samsung Medical Center
Condition:
Stereotactic Body Radiation Therapy (SBRT)
Oligometastasis
Oligoprogression
ctDNA
Patient-Reported Outcomes (PRO)
Intervention:
Radiation: Stereotactic body radiotherapy (SBRT)
Recruitment Status: Recruiting
Date of First Enrollment: May 1, 2025
Target Sample Size: 60
Countries of Recruitment:
Korea, Republic of
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07121335
Published by HT Digital Content Services with permission from Heal...